Recently, the emergence and vigorous development of targeted therapies, including B-cell Lymphoma 2 (Bcl-2) protein inhibitors and B-cell receptor (BCR) signal inhibitors have greatly improved the treatment options and prognosis of CLL (5). Here, BCR is linked to B-cell chronic lymphocytic leukemia.